SinTilimab After Radiation (STAR Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

November 30, 2023

Study Completion Date

April 30, 2024

Conditions
Carcinoma, Non-Small Cell Lung
Interventions
DRUG

Sintilimab

"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab."

Trial Locations (1)

100730

Department of Respiratory Medicine, Peking Union Medical College Hospita, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04167657 - SinTilimab After Radiation (STAR Study) | Biotech Hunter | Biotech Hunter